Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes

Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes and a Comparison of the Effect of Nicotinamide Riboside Supplementation on Brain NAD+ Levels

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02721537

Acronym

TRMC-004

Enrollment

Registered

2016-03-29

Start date

2016-09-30

Completion date

2022-08-31

Last updated

2022-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Concussion, Mild

Keywords

Brain Nicotinamide Adenine Dinucleotide (NAD+), Adenosine Triphosphate (ATP) Depletion, Polyadenosine Diphosphate-Ribosepolymerase (PARP) Activation

Brief summary

Can nicotinamide riboside (750 mg/day for 12 weeks) affect the levels of NAD+ in the brain as measured by 31P MRS?

Detailed description

Healthy collegiate athletes (football, soccer, rugby, hockey, and volleyball) will take Nicotinamide Riboside (NR) or placebo twice daily for 84 days. Pre- and post-intervention evaluations include physical assessment, blood tests for safety and toxicity monitoring, blood tests for biomarkers, neurologic testing, quality of life questionnaires, and the 31P MRI exam.

Interventions

DIETARY_SUPPLEMENTNicotinamide Riboside

Three capsules, twice per day for 84 days

OTHERMatching placebo

Three matching capsules, twice per day for 84 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adult current and former (within 2 years) collegiate athletes (football, rugby, soccer, hockey, and volleyball) * Body mass index (estimated based on height and weight) from 23 to 37 * Willing to provide informed consent, ingest test substance, and provide blood specimens * Willing to comply with study instructions and maintain current level of physical activity throughout the study

Exclusion criteria

* History of loss of consciousness of more than 5 minutes * Contraindications to Magnetic Resonance Imaging (MRI), such as implanted medical devices, metal objects, or pacemakers * History of epilepsy * History of more than 3 concussions * History of headache preceding a concussion * History of depression preceding a concussion * History of developmental delays or Attention Deficit Hyperactivity Disorder (ADHD) * History of post-traumatic seizures * History of complex spine and/or skull trauma

Design outcomes

Primary

Measure	Time frame	Description
Change in brain NAD+ levels	baseline, day 84	As measured by 31P MRI

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026